Novo Nordisk expands footprint in USA

Novo Nordisk realises a major expansion in Clayton, NC. The project will enhance Novo Nordisk’s manufacturing capabilities with more than 1.4 million square feet of new space​.

The expansion involves the collaboration with BE&K Building Group (BE&K) managing a new multi-product facility adjacent to Novo Nordisk’s existing operations in Clayton, North Carolina.​ BE&K has dedicated over two years of detailed preparation for this endeavor, providing estimates, schedules, and procurement strategies, and has begun construction. The ambitious project will involve the construction of ten or more buildings and multi-building combinations of the facility that will span approximately 56 acres.

The final state-of-the-art facility will be instrumental in manufacturing Novo Nordisk’s innovative treatments for obesity and other chronic diseases. Construction will gradually be finalized between 2027 and 2029.​“Clayton was the first manufacturing site for Novo Nordisk in the US, and this new, large-scale investment here confirms the continued importance of our production facilities in North Carolina. We are proud to be one of the cornerstones of our company’s growth,” said Niels Laurbjerg Nielsen, Corporate Vice President, Novo Nordisk. “We are honored to partner with Novo Nordisk on this transformative project,” said Frank Holley, CEO of BE&K. “Our team’s extensive preparation and dedication reflect our commitment to delivering world-class facilities that produce healthcare solutions benefiting the global population. This expansion will not only bolster Novo Nordisk’s manufacturing capabilities but will also contribute significantly to the local community and economy in North Carolina’s Triangle region.”​